128 related articles for article (PubMed ID: 27294334)
1. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
4. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
[TBL] [Abstract][Full Text] [Related]
7. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.
Valdez BC; Murray D; Nieto Y; Li Y; Wang G; Champlin RE; Andersson BS
Leuk Lymphoma; 2012 May; 53(5):973-81. PubMed ID: 22023523
[TBL] [Abstract][Full Text] [Related]
9. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS
Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
12. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Rakszawski K; Miki K; Claxton D; Wagner H; Shike H; Mineishi S; Naik S
Int J Hematol; 2018 Sep; 108(3):348-350. PubMed ID: 29542029
[TBL] [Abstract][Full Text] [Related]
14. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
[TBL] [Abstract][Full Text] [Related]
15. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
[TBL] [Abstract][Full Text] [Related]
16. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
[TBL] [Abstract][Full Text] [Related]
18. Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.
He X; Ye Y; Xu X; Wang J; Huang Y; Weng G; Zhang M; Guo K
Biomed Res Int; 2016; 2016():3071214. PubMed ID: 27843940
[TBL] [Abstract][Full Text] [Related]
19. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Bashir Q; Qazilbash MH; Andersson BS
Exp Hematol; 2020 Jan; 81():32-41. PubMed ID: 31954171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
